AI assistant
BioSyent Inc. — Earnings Release 2020
Nov 17, 2020
43507_rns_2020-11-17_2d1c2b1d-e101-4b3f-9193-6acc673861f9.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [109 x 41] intentionally omitted <==
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020
MISSISSAUGA, Ontario, Nov. 17, 2020 -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital and international business units.
As of the date of this press release, the Company has 12,808,600 common shares outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum President and CEO BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com